Plus Therapeutics Achieves Key Accreditation for CNSide Lab
Plus Therapeutics Achieves Key Accreditation for CNSide Lab
Certification critical to broad U.S. market release of the CNSide CSF Assay Platform
CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Lab Improvement Amendments (CLIA)
HOUSTON — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company striving to develop targeted radiotherapeutics for central nervous system cancers, has proudly announced the successful achievement of a certificate of accreditation from CMS for its laboratory. This milestone follows a planned laboratory audit, indicating that the lab meets all compliance standards set forth by the Clinical Laboratory Improvement Amendments (CLIA) enforced by CMS, which are essential federal guidelines for laboratories conducting human specimen testing.
Russ Bradley, President and General Manager of CNSide Diagnostics, expressed enthusiasm about this achievement, stating, “This is a key milestone on our trajectory to bring the CNSide cerebrospinal fluid (CSF) assay platform to the broadest possible set of patients with or at risk for CNS cancers and demonstrates our unwavering commitment to maintain the highest quality standards. Furthermore, this accreditation represents our latest tangible accomplishment in our market access strategy.”
The certification guarantees that laboratories comply with stringent requirements for proficiency testing, personnel qualifications, and quality control measures. Attaining this critical accreditation serves as a stepping stone toward achieving several additional important objectives, including:
Expanding Market Reach
One of the company's primary goals is obtaining state licensure in 48 out of 50 states, which is crucial for broader reach and patient access. Moreover, lab accreditation plays an essential role in ensuring comprehensive commercial insurance coverage. By obtaining this accreditation, Plus Therapeutics can secure reimbursement for testing services from a variety of private payors.
Meeting Regulatory Standards
In addition to reimbursement, lab accreditation is a mandatory requirement that enables the lab to participate in Medicare and Medicaid programs. This ensures that they can receive payments for essential testing services that may benefit numerous patients with CNS cancers.
Furthermore, this accreditation is crucial for the expansion of payment coding, helping the company in their pursuit of unique reimbursement billing codes.
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a proud subsidiary of Plus Therapeutics, Inc. dedicated to creating proprietary laboratory-developed tests, notably the CNSide platform. This innovative platform is designed specifically for identifying tumor cells that have metastasized to the central nervous system in patients suffering from carcinomas and melanomas.
Utilizing Advanced Technology
The CNSide CSF Assay Platform allows for quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA present in the cerebrospinal fluid, informing healthcare providers and enhancing the management of patients affected by leptomeningeal metastases.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is at the forefront of developing targeted radiotherapeutics specifically aimed at treating difficult cancers located within the central nervous system. The company combines advanced image-guided local beta radiation with targeted drug delivery techniques, driving innovation within its product pipeline, specifically addressing challenges such as leptomeningeal metastases and recurrent glioblastoma.
Plus Therapeutics has established a robust supply chain through strategic partnerships, enabling them to advance the development and potential future commercialization of its therapeutic products.
Frequently Asked Questions
What is CNSide Diagnostics?
CNSide Diagnostics is a subsidiary of Plus Therapeutics that specializes in developing laboratory tests for detecting cancer cells in the central nervous system.
What recent achievement did Plus Therapeutics announce?
Plus Therapeutics announced that its subsidiary CNSide Diagnostics received a certificate of accreditation from CMS for its laboratory, ensuring compliance with federal standards.
Why is lab accreditation important?
Lab accreditation ensures that the laboratory meets necessary proficiency testing and quality control standards, enabling access to Medicare and Medicaid coverage and broader market reach.
What technologies does Plus Therapeutics utilize?
Plus Therapeutics employs advanced image-guided beta radiation and targeted drug delivery techniques to develop its therapeutic products for CNS cancers.
How does the CNSide CSF Assay Platform assist healthcare providers?
The CNSide CSF Assay Platform provides quantitative analysis of tumor cells, aiding healthcare providers in the management of patients with leptomeningeal metastases.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.